-
EP3689355
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3689355
| EP3689355 - PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 03.07.2020 Database last updated on 31.08.2024 | |
| Former | The international publication has been made Status updated on 02.02.2019 | Most recent event Tooltip | 15.05.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Lemonex Inc. Sillim-dong Seoul National University 1 Gwanak-ro Gwanak-gu Seoul 08826 / KR | [2020/32] | Inventor(s) | 01 /
WON, Cheol Hee (Nakseongdae Hyundai Hometown Bongcheon-dong) 301-803 16 Solbat-ro 7-gil Gwanak-gu Seoul 08741 / KR | [2020/32] | Representative(s) | dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB Deichmannhaus am Dom Bahnhofsvorplatz 1 50667 Köln / DE | [2020/32] | Application number, filing date | 18838318.6 | 30.07.2018 | [2020/32] | WO2018KR08611 | Priority number, date | US201762538034P | 28.07.2017 Original published format: US 201762538034 P | [2020/32] | Filing language | KO | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2019022586 | Date: | 31.01.2019 | Language: | KO | [2019/05] | Type: | A2 Application without search report | No.: | EP3689355 | Date: | 05.08.2020 | Language: | EN | [2020/32] | Search report(s) | International search report - published on: | KR | 04.07.2019 | (Supplementary) European search report - dispatched on: | EP | 10.08.2021 | Classification | IPC: | C12N15/113, A61K31/713, A61K9/51, A61P35/00 | [2021/18] | CPC: |
C12N15/111 (EP);
A61K48/00 (KR);
A61K31/713 (EP,CN,US);
A61K31/715 (KR);
A61K47/02 (CN);
A61K9/0019 (EP);
A61K9/143 (EP);
A61K9/51 (EP);
A61K9/5115 (EP,KR);
A61P1/16 (EP);
A61P35/00 (EP,CN,KR,US);
C12N15/113 (EP,US);
|
| Former IPC [2020/32] | A61K31/713, A61K9/51, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/32] | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR VORBEUGUNG ODER BEHANDLUNG VON LEBERKREBS | [2020/32] | English: | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER | [2020/32] | French: | TRAITEMENTS PHARMACEUTIQUES POUR PRÉVENIR OU TRAITER LE CANCER DU FOIE | [2020/32] | Entry into regional phase | 25.02.2020 | Translation filed | 25.02.2020 | National basic fee paid | 25.02.2020 | Search fee paid | 25.02.2020 | Designation fee(s) paid | 25.02.2020 | Examination fee paid | Examination procedure | 25.02.2020 | Examination requested [2020/32] | 04.03.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 29.07.2020 | Renewal fee patent year 03 | 29.07.2021 | Renewal fee patent year 04 | 28.07.2022 | Renewal fee patent year 05 | 27.07.2023 | Renewal fee patent year 06 | 15.05.2024 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]WO2005116204 (RNAI CO LTD [JP], et al) [I] 1-15 * sequences 22171,455895,222229-222245 *; | [I]WO2009079452 (BRIGHAM & WOMENS HOSPITAL [US], et al) [I] 1,2,5,7-15 * page 71; claim 1; sequence 936 *; | [A]WO2009080898 (OULUN YLIOPISTO [FI], et al) [A] 1,2,5,7-15; | [I]WO2009140676 (IMMUNE DISEASE INST INC [US], et al) [I] 1-4,7-14 * page 69; sequence 52 *; | [I]WO2010134939 (ZIRUS INC [US], et al) [I] 1,2,5,7-15 * page 74; sequences 1839-1840 *; | [A]WO2012139081 (UNIV LEICESTER [GB], et al) [A] 1-15; | [I]KR20170023335 (KOREA INST RADIOLOGICAL & MEDICAL SCIENCES [KR]) [I] 1,2,5,7-15 * claim 4; sequence 4 *; | [A] - LEE SO JIN ET AL, "Delivery strategies and potential targets for siRNA in major cancer types", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, (20160531), vol. 104, doi:10.1016/J.ADDR.2016.05.010, ISSN 0169-409X, pages 2 - 15, XP029651118 [A] 1-15 DOI: http://dx.doi.org/10.1016/j.addr.2016.05.010 | [IP] - QINGYU SHEN ET AL, "Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma : Shen, Eun, et al.", HEPATOLOGY, (20180401), vol. 67, no. 4, doi:10.1002/hep.29606, ISSN 0270-9139, pages 1360 - 1377, XP055630132 [IP] 1-15 * the whole document * DOI: http://dx.doi.org/10.1002/hep.29606 | [P] - Shen Qingyu; ET AL, "Supporting Information BANF1, PLOD3, SF3B4 as Early-stage Cancer Decision Markers and Drivers of Hepatocellular Carcinoma Supplementary Material and Methods CELL CULTURE", (20180401), URL: https://aasldpubs.onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fhep.29606&file=hep29606-sup-0001-suppinfo1.pdf, (20210309), XP055783287 | [I] - MAO LANGYONG ET AL, "BANF1 Is Downregulated by IRF1-Regulated MicroRNA-203 in Cervical Cancer", PLOS ONE, vol. 10, no. 2, doi:10.1371/journal.pone.0117035, (20150206), page e0117035, URL: https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.pone.0117035/1/pone.0117035.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa@plos-prod.iam.gserviceaccount.com/20210304/auto/storage/goog4_request&X-Goog-Date=20210304T134354Z&X-Goog-Expires=3600&X-Goog-SignedHeaders=ho, XP055782167 [I] 1-4,7-14 * figures 6,7 * DOI: http://dx.doi.org/10.1371/journal.pone.0117035 | [ ] - Anonymous, "WO 2005116204-A/22171: Double strand polynucleotides generating RNA in - Nucleotide - NCBI", (20110418), URL: https://www.ncbi.nlm.nih.gov/nuccore/FW615645.1, XP055783046 | [ ] - Anonymous, "WO 2005116204-A/455895: Double strand polynucleotides generating RNA i - Nucleotide - NCBI", (20110419), URL: https://www.ncbi.nlm.nih.gov/nuccore/FZ049370.1, XP055783051 | [ ] - Anonymous, "WO 2005116204-A/46962: Double strand polynucleotides generating RNA in - Nucleotide - NCBI", (20110418), URL: https://www.ncbi.nlm.nih.gov/nuccore/FW640436, (20210630), XP055819800 | [ ] - Anonymous, "WO 2005116204-A/46963: Double strand polynucleotides generating RNA in - Nucleotide - NCBI", (20110418), URL: https://www.ncbi.nlm.nih.gov/nuccore/FW640437, (20210630), XP055819801 | [ ] - Anonymous, "WO 2005116204-A/222231: Double strand polynucleotides generating RNA i - Nucleotide - NCBI", (20110418), URL: https://www.ncbi.nlm.nih.gov/nuccore/FW815705, (20210701), XP055820216 | [A] - CHEN YIJIE ET AL, "Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier", BIOMATERIALS, ELSEVIER, AMSTERDAM, NL, (20140929), vol. 35, no. 38, doi:10.1016/J.BIOMATERIALS.2014.09.003, ISSN 0142-9612, pages 10058 - 10069, XP029074751 [A] 1-15 DOI: http://dx.doi.org/10.1016/j.biomaterials.2014.09.003 | [A] - KIM WANIL; ET AL, "Obtusilactone B from Machilus Thunbergii targets barrier-to-autointegration factor to treat cancer.", MOLECULAR PHARMACOLOGY, (20130201), vol. 83, pages 367 - 376, XP055783026 [A] 1-15 | [A] - B.H. JOSHI ET AL, "siRNA: novel therapeutics from functional genomics", BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, (20140102), vol. 30, no. 1, doi:10.1080/02648725.2014.921495, ISSN 0264-8725, pages 1 - 30, XP055209019 [A] 1-15 DOI: http://dx.doi.org/10.1080/02648725.2014.921495 | [AP] - SHEN QINGYU ET AL, "SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma", BMB REPORTS, (20180228), vol. 51, no. 2, doi:10.5483/BMBRep.2018.51.2.021, pages 57 - 58, XP055818583 [AP] 1-15 DOI: http://dx.doi.org/10.5483/BMBRep.2018.51.2.021 | [AP] - Tsai Chia-Kuang ET AL, "Overexpression of PLOD3 promotes tumor progression and poor prognosis in gliomas INTRODUCTION", Oncotarget, (20180320), pages 15705 - 15720, URL: https://www.oncotarget.com/article/24594/pdf/, (20210628), XP055818589 [AP] 1,2,5,7-15 | [A] - WENTAO ZHOU ET AL, "SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells", TUMOR BIOLOGY, (20170301), pages 1 - 9, URL: https://journals.sagepub.com/doi/pdf/10.1177/1010428317695913, XP055820222 [A] 1,2,6-15 | [A] - Qingyu Shen, "Abstract 4472: A subunit of splicing factor 3b, SF3B4, functions as driver of liver cancer via aberrant splicing activity on tumor suppressor KLF4 | Cancer Research", (20170405), URL: https://cancerres.aacrjournals.org/content/77/13_Supplement/4472, (20210701), XP055820221 [A] 1,2,6-15 | International search | [Y]US2014342946 (KURIAKOSE MONI ABRAHAM [IN], et al) [Y] 1-15 * See abstract; claims 1-7. *; | [A]KR20110060209 (KOREA RES INST OF BIOSCIENCE [KR]) [A] 1-15 * See the entire document. *; | [A]KR101150410B (THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION) [A] 1-15 * See the entire document. *; | [A]KR101077179B (IN-D-UST-RY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY) [A] 1-15 * See the entire document. * | [Y] - IGUCHI, TOMOHIRO et al., "Increased Copy Number of the Gene Encoding SF3B4 Indicates Poor Prognosis in Hepatocellular Carcinoma", Anticancer Research, (20160000), vol. 36, no. 5, pages 2139 - 2144, XP055623564 [Y] 1-15 * See abstract; page 2141, Result section. * | by applicant | - "pharmaceutical Science", REMINGTON, U.S.P, Mack Publishing Company |